Pfizer, Genmab Get Speedy FDA Review of Tivdak Full Approval
By Colin Kellaher
Pfizer and Genmab on Tuesday said the U.S. Food and Drug Administration granted priority review to their request to convert the accelerated approval of Tivdak for certain patients with cervical cancer to full approval.
The companies said the FDA has set a target action date of May 9 for the application, which is based on positive results from a global Phase 3 study that showed overall survival benefit of Tivdak over chemotherapy in patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.
The FDA granted accelerated approval to Tivdak in September 2021.
Copenhagen biotechnology company Genmab and Seagen, which New York-based Pfizer acquired last year in a $43 billion deal, are co-developing Tivdak by Genmab and Seagen, under an agreement in which the companies share costs and profits for the product on a 50-50 basis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 09, 2024 07:30 ET (12:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks